Cureledger
Cureledger operates a legal life-data trust that lets patients with rare disorders contribute their health data under personally set terms. The trust de-identifies data for qualified researchers while ensuring patients retain ownership, control re-identification keys, and share in any revenue generated. By centralizing high-quality, patient-governed data, Cureledger accelerates AI-driven drug development for small populations under the FDA’s Plausible Mechanism Framework.
- Healthcare Technology
- Drug Discovery & Therapeutics
- Legal Technology
- Digital Health
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Drug development has historically bypassed rare disease populations because their small numbers make conventional pharmaceutical economics unviable, and the research labor required was too expensive to justify. This has left patients without therapies, despite the science being available, and has created a data gap that now limits the potential of AI-driven drug discovery.
Solution
Cureledger is a legal life-data trust that enables patients with rare disorders to contribute their health data under terms they personally set. A trustee holds the data under a fiduciary duty, and qualified researchers can access it only on those terms. The data is de-identified before leaving the trust, with patients holding the re-identification key, and they share in any revenue generated. This structure ensures data remains available for future research programs even if a sponsor shuts down, and patients can choose what findings they want to be told about. By centralizing high-quality, patient-governed data, Cureledger aims to accelerate AI-driven drug development for small populations under the FDA’s Plausible Mechanism Framework.
Target Audience
Primary users are patients and families affected by rare disorders who want to contribute their health data to accelerate research, as well as qualified researchers and drug developers seeking high-quality, patient-governed data for AI-driven drug development.
Features
- Legal trust structure with a fiduciary trustee holding patient data under individually set terms
- De-identification of data before it leaves the trust, with patients holding the re-identification key
- Revenue-sharing model where patients receive a share of the income their data produces
- Standing terms that persist even if a sponsor or AI lab changes direction, preventing bankruptcy auctions or second sales
- Patient-controlled notification preferences for research findings, new therapies, or qualifying trials
- Data remains in the trust and available for future programs, compounding value with each participant